Herbalife Ltd. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Shareholders' Deficit - Additional Information (Detail)

Shareholders' Deficit - Additional Information (Detail) $ / shares in Units, $ in Millions		1 Months Ended	3 Months Ended			12 Months Ended
	Oct. 30, 2018 USD ($)	Feb. 28, 2014 USD ($) $ / shares shares	Mar. 31, 2019 USD ($) $ / shares shares	Mar. 31, 2018 USD ($) $ / shares shares	Mar. 31, 2014 USD ($)	Dec. 31, 2018 USD ($) shares	Oct. 31, 2017 USD ($)
Stockholders Equity [Line Items]
Share repurchase program authorized amount	$ 1,500.0		$ 1,500.0
Share repurchase program, remaining authorized capacity	$ 113.3		$ 1,500.0
Share repurchase program expiration date	Feb. 21, 2020		Oct. 30, 2023
Forward counterparties shares purchased and subsequently retired \| shares			2,000,000
Accumulated deficit			$ (430.0)			$ (526.3)
Repurchase of common stock, shares \| shares			100,000	1,100,000
Treasury stock shares, at cost \| shares			10,000,000			10,000,000
Shares repurchases, inclusive of transaction costs and issuance of CVR value			$ 0.0	$ 0.3
Withheld for tax purpose for share-based compensation plans			7.6	49.7
Shares repurchases, value			7.6	50.0
Payments for share repurchases			7.6	54.2
Payments for share repurchases from prior period liability				4.2
Terminating result of portion of capped call transactions cash received				27.1
Other comprehensive income before foreign currency translation adjustments reclassifications, tax expense			$ 0.5	1.1
Capped call transactions [Member]
Stockholders Equity [Line Items]
Capped call transactions with financial institutions		$ 123.8
Capped call transactions price per common share \| $ / shares		$ 60.39
Increase (decrease) in additional paid-in capital, other					$ (123.8)
Terminating result of portion of capped call transactions cash received						$ 55.9
Capped call transactions [Member] \| Convertible Senior Notes Due 2019 [Member]
Stockholders Equity [Line Items]
Convertible notes conversion price \| $ / shares		$ 43.14
Capped call transactions [Member] \| Common Shares [Member]
Stockholders Equity [Line Items]
Weighted-average adjusted cap price per common share \| $ / shares			54.24
Prepaid forward share repurchase transactions [Member]
Stockholders Equity [Line Items]
Forward share repurchase transactions amount		$ 685.8			685.8
Forward transactions, shares to be purchased \| shares		19,900,000
Average cost per share of shares repurchased \| $ / shares		$ 34.51
Settlement date of forward transactions			Aug. 15, 2019
Forward counterparties shares purchased and subsequently retired \| shares			2,000,000
Non-cash interest expense relating to unamortized non-cash issuance costs			$ 0.2
Shares outstanding under forward purchasing transactions \| shares			4,000,000
Accumulated deficit					(653.9)
Additional paid-in-capital					(31.9)
Non-cash forward transaction issuance costs					$ 35.8
Non-cash interest expense relating to amortization of non-cash issuance costs			$ 0.7	$ 1.6
Open market purchases [Member] \| Indirect wholly owned subsidiary [Member]
Stockholders Equity [Line Items]
Average cost per share of shares repurchased \| $ / shares				$ 33.90
Repurchase of common stock, shares \| shares				8,400
Repurchase of common stock, value				$ 0.3
October 2017 Dutch Auction Tender Offer [Member]
Stockholders Equity [Line Items]
Forward share repurchase transactions amount			$ 1.6
Contingent value right agreement term			2 years
Non-transferable contractual contingent value right agreement initial fair value							$ 7.3
CVR expiration period			2019-08
Gain (loss) recognized in other (income) expense			$ 8.5	$ (11.3)
Non-transferable contractual contingent value right agreement change in fair value			$ 7.2			$ 15.7